Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects

University of Aarhus

Status: Completed

Conditions: Metabolic Diseases; Acromegaly

Treatments: Drug: genotropin

Study type: Interventional

Funder types: Other

Identifiers

NCT01723748

1-10-72-491-12

35197 (Other Identifier)

Details and patient eligibility

About

The treatment with SA still leaves some questions unanswered. Firstly, SA treatment often results in a concomitant suppression of the insulin secretion, which might lead to clinically significant glucose intolerance. Secondly, the traditional evaluation of disease activity by measuring circulating levels of GH and total IGF-I is not reliable enough

Hypotheses: Treatment of acromegaly with SA versus surgery alone is associated with:

• Glucose intolerance despite normalized insulin sensitivity
• Modified peripheral GH activity in peripheral target organs assessed on molecular endpoints

Full description

Acromegaly is a rare disease usually caused by a benign growth hormone (GH) producing pituitary adenoma. In case of inadequate disease control, the condition is associated with significant morbidity and approximately a doubling of mortality compared to the background population. Medical treatment with somatostatin analogues (SA) has been employed for about 20 years and is a well-established treatment in cases where surgery is impossible or inadequate. The treatment with SA still leaves some questions unanswered. Firstly, SA treatment often results in a concomitant suppression of the insulin secretion, which might lead to clinically significant glucose intolerance. Secondly, the traditional evaluation of disease activity by measuring circulating levels of GH and total IGF-I is not reliable enough

Enrollment: 18 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• > 18 years
• treated acromegaly
• considered suitable

Exclusion criteria

• pregnancy

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

18 participants in 2 patient groups

surgery treated

Active Comparator group

Description:

10 patients with well-controlled acromegaly for at least 6 months after surgery alone. Stimulated with genotropin

Treatment:

Drug: genotropin

SA treated

Active Comparator group

Description:

10 patients with well-controlled acromegaly for at least 6 months after SA treatment Stimulated with genotropin

Treatment:

Drug: genotropin